Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · IEX Real-Time Price · USD
3.330
+0.060 (1.83%)
Jul 12, 2024, 4:00 PM EDT - Market closed
1.83%
Market Cap 106.27M
Revenue (ttm) 2.00M
Net Income (ttm) -27.92M
Shares Out 31.91M
EPS (ttm) -38.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 321,904
Open 3.370
Previous Close 3.270
Day's Range 3.270 - 3.390
52-Week Range 2.130 - 20.710
Beta n/a
Analysts Buy
Price Target 35.80 (+975.08%)
Earnings Date Aug 19, 2024

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2023
Employees 8
Stock Exchange NASDAQ
Ticker Symbol SGMT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $35.8, which is an increase of 975.08% from the latest price.

Price Target
$35.8
(975.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET

4 weeks ago - GlobeNewsWire

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance f...

5 weeks ago - GlobeNewsWire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet's topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH Dr. Scott Friedman to present unmet need in MASH...

2 months ago - GlobeNewsWire

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024

2 months ago - GlobeNewsWire

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors ...

2 months ago - GlobeNewsWire

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors ...

2 months ago - GlobeNewsWire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 Sagimet annou...

2 months ago - GlobeNewsWire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor...

3 months ago - GlobeNewsWire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor...

3 months ago - GlobeNewsWire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis

3 months ago - GlobeNewsWire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

4 months ago - GlobeNewsWire

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibit...

6 months ago - GlobeNewsWire

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibit...

6 months ago - GlobeNewsWire

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis -  Primary efficacy endpo...

6 months ago - PRNewsWire

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis

6 months ago - GlobeNewsWire

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

7 months ago - GlobeNewsWire

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

8 months ago - GlobeNewsWire

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

8 months ago - GlobeNewsWire

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024

8 months ago - GlobeNewsWire

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fi...

8 months ago - GlobeNewsWire

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

9 months ago - GlobeNewsWire

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that tar...

9 months ago - GlobeNewsWire

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli...

10 months ago - GlobeNewsWire

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Completed upsized initial public offering raising $96.4 million in gross proceeds Presented positive data at EASL Congress 2023 from the planned interim readout of the Phase 2b FASCINATE-2 trial in NA...

11 months ago - GlobeNewsWire

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunction...

11 months ago - GlobeNewsWire